Bicycle Immune Cell Agonists (BICAs)
Immuno-oncology
Discovery/PreclinicalActive
Key Facts
About Bicycle Therapeutics
Bicycle Therapeutics is a UK-based, NASDAQ-listed biotech pioneering a novel class of synthetic, constrained peptide therapeutics. Its core Bicycle® platform generates molecules designed to deliver the high specificity of biologics with the favorable pharmacokinetics of small molecules, enabling deep tissue penetration in solid tumors. The company has advanced multiple wholly-owned and partnered programs into clinical development, focusing on oncology targets like Nectin-4 and EphA2, while actively exploring partnerships to expand into other therapeutic areas. Its strategy is to build a leading solid tumor medicine portfolio, validated by clinical data and strategic collaborations.
View full company profileTherapeutic Areas
Other Immuno-oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| PD-1/PD-L1 Inhibitor Binding Assay Kit | Aurora Biolabs | Commercial |
| CTLA-4/B7-1 Inhibitor Screening Kit | Aurora Biolabs | Commercial |
| OX40 & PD-1 Assay | Aurora Biolabs | Commercial |
| HPK1 inhibitor | Acellera | Pre-clinical |
| SKP2-CKS1 PPI Inhibitor | Iktos | Hit-to-Lead |
| PD-1 Expression Inhibitor | BCN Biosciences | Preclinical |
| CCR8 ADC | Integral Molecular | Preclinical |
| KB16A | KBio | Discovery |
| NeoSight Neoantigen Detection | ReproCELL | Research/Clinical |
| EMUNKITUG (HFB200301) | HiFiBiO Therapeutics | Phase 1 |
| HFB200603 | HiFiBiO Therapeutics | Phase 1 |
| Undisclosed Multispecific Therapeutics | ModeX Therapeutics | Pre-clinical |